NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had clinically meaningful and significant improvement in symptoms, results of the phase 3 ...

In 2023, in the 7MM the total wAIHA market size was ~ USD 300 million. Emerging therapies for Warm Autoimmune Hemolytic Anemia, including Obexelimab (ZB012), Nipocalimab (M281), and others, are ...

Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

/ -- Autoimmune hemolytic anemia (AIHA) treatment encompasses a range of therapeutic strategies aimed at mitigating the immune system's attack on red blood cells, thereby alleviating anemia and ...

The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term complications of sickle cell ...

Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is currently the only approved treatment for CAD and is a ...

Breakthrough Therapy Designation for nipocalimab based on results from the Phase 2 UNITY clinical trial for HDFN Phase 3 clinical trial enrollment underway, representing the only therapy reported to ...

Case 1. A 17-year-old boy was admitted to Walter Reed General Hospital for repair of an ostium-primum defect of the interatrial septum with an associated cleft mitral valve and mitral insufficiency.

P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia PURPOSE: Past reports ...

"Warm Autoimmune Hemolytic Anemia Market"In 2023, in the 7MM the total wAIHA market size was ~ USD 300 million. Emerging therapies for Warm Autoimmune Hemolytic Anemia, including Obexelimab (ZB012), ...

Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Paris, November 17, 2022. The European Commission (EC) has ...